Paliperidone

Paliperidone is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Paliperidone is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain.

Paliperidone comes as an extended-release (long-acting) tablet to take by mouth. It is usually taken once a day in the morning with or without food. Take paliperidone at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take paliperidone exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the tablets whole with plenty of water or other liquid. Do not split, chew, or crush the tablets. Tell your doctor if you cannot swallow tablets. Your doctor will probably prescribe another medication to treat your condition.

Talk to your doctor about how you are feeling during your treatment. If your symptoms are still bothersome, your doctor may gradually increase your dose, not more often than once every 5 days.

Paliperidone controls the symptoms of schizophrenia but does not cure the condition. Continue to take paliperidone even if you feel well. Do not stop taking paliperidone without talking to your doctor.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking paliperidone,

• tell your doctor and pharmacist if you are allergic to paliperidone, risperidone (Risperdal), or any other medications.

• tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: antidepressants; certain antibiotics such as erythromycin (E.E.S., E-Mycin, Erythrocin), gatifloxacin (Tequin) (not available in the United States), moxifloxacin (Avelox), and sparfloxacin (Zagam); certain antipsychotics such as chlopromazine (Sonazine, Thorazine), pimozide (Orap), risperidone (Risperdal) and thioridazine; cisapride (Propulsid); levodopa (in Sinemet, in Stalevo); medications for anxiety, high blood pressure, or seizures; medications for irregular heartbeat such as amiodarone (Cordarone), disopyramide (Norpace), dofetilide (Tikosyn); procainamide (Procanbid, Pronestyl), quinidine (Quinidex), and sotalol (Betapace, Betapace AF); sedatives; sleeping pills; and tranquilizers. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

• tell your doctor if you have or have ever had a prolonged QT interval (a rare heart problem that may cause fainting or irregular heartbeat); slow or irregular heartbeat; a heart attack; low levels of potassium or magnesium in your blood; seizures; trouble keeping your balance; a stroke; a head injury; a brain tumor; Parkinson's disease (a disorder of the nervous system that causes difficulties with movement, muscle control, and balance); diabetes; breast cancer; surgery involving the intestines; any condition that causes blockage or narrowing of the esophagus (tube that connects the mouth and stomach), stomach, or intestines such as cystic fibrosis (an inborn disease that causes problems with breathing, digestion, and reproduction), and inflammatory bowel disease (IBD; a group of conditions that cause swelling of the lining of the intestines); and kidney, heart, or liver disease. Also tell your doctor if you drink or have ever drunk large amounts of alcohol and if you use or have ever used street drugs or have overused prescription medications. Tell your doctor if you have ever had to stop taking a medication for mental illness because of severe side effects.

• tell your doctor if you are pregnant, especially if you are in the last few months of your pregnancy, or if you plan to become pregnant or are breast-feeding. If you become pregnant while taking paliperidone, call your doctor. Paliperidone may cause problems in newborns following delivery if it is taken during the last months of pregnancy.

• if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking paliperidone.

• you should know that paliperidone may make you drowsy and may cause difficulty with thinking and movement. Do not drive a car or operate machinery until you know how this medication affects you.

• you should know that alcohol may add to the drowsiness caused by paliperidone. Do not drink alcoholic beverages while you are taking this medication.

• you should know that you may experience hyperglycemia (increases in your blood sugar) while you are taking this medication, even if you do not already have diabetes. If you have schizophrenia, you may be more likely to develop diabetes than people who do not have schizophrenia, and taking paliperidone or similar medications may increase this risk. Tell your doctor immediately if you have any of the following symptoms while you are taking paliperidone: extreme thirst, frequent urination, extreme hunger, blurred vision, or weakness. It is very important to call your doctor as soon as you have any of these symptoms, because high blood sugar can cause more serious symptoms, such as dry mouth, nausea and vomiting, shortness of breath, breath that smells fruity, or decreased consciousness, and may become life-threatening if it is not treated at an early stage.

• you should know that paliperidone may make it harder for your body to cool down when it gets very hot. Tell your doctor if you plan to exercise or be exposed to extreme heat.

• you should know that paliperidone may cause dizziness, lightheadedness, and fainting when you get up too quickly from a lying position. This is more common when you first start taking paliperidone or when your dose is increased. To avoid this problem, get out of bed slowly, resting your feet on the floor for a few minutes before standing up.

Unless your doctor tells you otherwise, continue your normal diet.

Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

• Paliperidone may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

  • dizziness, feeling unsteady, or having trouble keeping your balance

  • extreme tiredness

  • weakness

  • headache

  • dry mouth

  • increased saliva

  • weight gain

  • stomach pain

• Some side effects can be serious. If you experience any of these symptoms or those listed in the IMPORTANT WARNING section, call your doctor immediately:

  • fever

  • muscle pain or stiffness

  • falling

  • confusion

  • fast, pounding, or irregular heartbeat

  • sweating

  • unusual movements of your face or body that you cannot control

  • slow or stiff movements

  • restlessness

  • painful erection of the penis that lasts for hours

• Paliperidone may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include:

• unusual movements of your face or body that you cannot control

• slow or stiff movements

• restlessness

• unsteadiness

• drowsiness

• fast heartbeat

Keep all appointments with your doctor.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

You may notice something that looks like a tablet in your stool. This is just the empty tablet shell and does not mean that you did not get your complete dose of medication.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug	Interaction
Moxifloxacin	Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Paliperidone.
Repaglinide	Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Paliperidone.
Insulin Glargine (rDNA origin) Injection	Insulin Glargine (rDNA origin) Injection The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Paliperidone.
Delavirdine	Delavirdine The metabolism of Paliperidone can be decreased when combined with Delavirdine.
Nevirapine	Nevirapine The metabolism of Paliperidone can be decreased when combined with Nevirapine.
Atorvastatin	Atorvastatin The metabolism of Paliperidone can be decreased when combined with Atorvastatin.
Dolasetron	Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Paliperidone.
Anagrelide	Anagrelide The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Paliperidone.
Candesartan	Candesartan Paliperidone may decrease the antihypertensive activities of Candesartan.
Cilostazol	Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Paliperidone.
Clopidogrel	Clopidogrel The metabolism of Paliperidone can be decreased when combined with Clopidogrel.
Diphenoxylate	Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Paliperidone.
Erythromycin and Sulfisoxazole	Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Paliperidone.
Estrogen and Progestin (Oral Contraceptives)	Estrogen and Progestin (Oral Contraceptives) Conjugated estrogens may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Fenofibrate	Fenofibrate Fenofibrate may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Guanfacine	Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Paliperidone.
Magnesium Hydroxide	Magnesium Hydroxide Paliperidone may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Methylergonovine	Methylergonovine The risk or severity of hypertension can be increased when Methylergometrine is combined with Paliperidone.
Miglitol	Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Paliperidone.
Mycophenolate	Mycophenolate Mycophenolic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Naratriptan	Naratriptan The risk or severity of adverse effects can be increased when Naratriptan is combined with Paliperidone.
Olsalazine	Olsalazine Olsalazine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Paregoric	Paregoric The serum concentration of Morphine can be increased when it is combined with Paliperidone.
Penbutolol	Penbutolol The risk or severity of QTc prolongation can be increased when Acebutolol is combined with Paliperidone.
Pentazocine	Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Paliperidone.
Potassium	Potassium Potassium may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Prednisone	Prednisone Prednisone may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Ranitidine	Ranitidine The metabolism of Paliperidone can be decreased when combined with Ranitidine.
Reserpine	Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Paliperidone.
Rizatriptan	Rizatriptan The risk or severity of adverse effects can be increased when Rizatriptan is combined with Paliperidone.
Sumatriptan	Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Paliperidone.
Tacrolimus	Tacrolimus The metabolism of Paliperidone can be decreased when combined with Tacrolimus.
Tizanidine	Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Paliperidone.
Triamcinolone	Triamcinolone The metabolism of Paliperidone can be increased when combined with Triamcinolone.
Zolmitriptan	Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Paliperidone.
Ampicillin Injection	Ampicillin Injection Ampicillin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Doxycycline Injection	Doxycycline Injection Doxycycline may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Famotidine Injection	Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Paliperidone.
Fluconazole Injection	Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Paliperidone.
Foscarnet Injection	Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Paliperidone.
Hydromorphone Injection	Hydromorphone Injection The risk or severity of adverse effects can be increased when Hydromorphone is combined with Paliperidone.
Levofloxacin Injection	Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Paliperidone.
Meperidine Injection	Meperidine Injection The risk or severity of adverse effects can be increased when Meperidine is combined with Paliperidone.
Metoclopramide Injection	Metoclopramide Injection The risk or severity of adverse effects can be increased when Metoclopramide is combined with Paliperidone.
Metronidazole Injection	Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Paliperidone.
Morphine Injection	Morphine Injection The serum concentration of Morphine can be increased when it is combined with Paliperidone.
Pamidronate Injection	Pamidronate Injection Pamidronic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Vancomycin Injection	Vancomycin Injection Paliperidone may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Altretamine	Altretamine The therapeutic efficacy of Paliperidone can be decreased when used in combination with Amphetamine.
Cefuroxime	Cefuroxime Cefuroxime may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cyclosporine	Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Paliperidone.
Ondansetron	Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Paliperidone.
Granisetron	Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Paliperidone.
Torsemide	Torsemide Torasemide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Olanzapine	Olanzapine Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Alosetron	Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Paliperidone.
Dofetilide	Dofetilide The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Paliperidone.
Entacapone	Entacapone The therapeutic efficacy of Entacapone can be decreased when used in combination with Paliperidone.
Eprosartan	Eprosartan Paliperidone may decrease the antihypertensive activities of Eprosartan.
Hydroxychloroquine	Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Paliperidone.
Meloxicam	Meloxicam Meloxicam may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Oxcarbazepine	Oxcarbazepine The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Paliperidone.
Pantoprazole	Pantoprazole Pantoprazole may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Telmisartan	Telmisartan Paliperidone may decrease the antihypertensive activities of Telmisartan.
Temozolomide	Temozolomide Temozolomide may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Zaleplon	Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Paliperidone.
Anakinra	Anakinra The metabolism of Paliperidone can be increased when combined with Anakinra.
Desloratadine	Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Paliperidone.
Linezolid	Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Paliperidone.
Trimipramine	Trimipramine Trimipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Etanercept Injection	Etanercept Injection The metabolism of Paliperidone can be increased when combined with Etanercept.
Glycopyrrolate	Glycopyrrolate Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
Modafinil	Modafinil The metabolism of Paliperidone can be increased when combined with Modafinil.
Perindopril	Perindopril Perindopril may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Tenofovir	Tenofovir Tenofovir may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Choline Magnesium Trisalicylate	Choline Magnesium Trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Sirolimus	Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Paliperidone.
Dutasteride	Dutasteride The metabolism of Paliperidone can be decreased when combined with Dutasteride.
Epinephrine Injection	Epinephrine Injection The therapeutic efficacy of Epinephrine can be decreased when used in combination with Paliperidone.
Eplerenone	Eplerenone Eplerenone may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Escitalopram	Escitalopram The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Paliperidone.
Olmesartan	Olmesartan Paliperidone may decrease the antihypertensive activities of Olmesartan.
Zonisamide	Zonisamide The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Paliperidone.
Adalimumab Injection	Adalimumab Injection The metabolism of Paliperidone can be increased when combined with Adalimumab.
Aripiprazole	Aripiprazole Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Atomoxetine	Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Paliperidone.
Dexmethylphenidate	Dexmethylphenidate The risk or severity of adverse effects can be increased when Paliperidone is combined with Dexmethylphenidate.
Atazanavir	Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Paliperidone.
Almotriptan	Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Paliperidone.
Eletriptan	Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Paliperidone.
Mefloquine	Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Paliperidone.
Rosuvastatin	Rosuvastatin The metabolism of Paliperidone can be decreased when combined with Rosuvastatin.
Vardenafil	Vardenafil The serum concentration of Vardenafil can be increased when it is combined with Paliperidone.
Alfuzosin	Alfuzosin Alfuzosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Aprepitant	Aprepitant The metabolism of Paliperidone can be decreased when combined with Aprepitant.
Emtricitabine	Emtricitabine Emtricitabine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Memantine	Memantine The therapeutic efficacy of Memantine can be decreased when used in combination with Paliperidone.
Tegaserod	Tegaserod The metabolism of Tegaserod can be decreased when combined with Paliperidone.
Tadalafil	Tadalafil The risk or severity of hypotension, dyspepsia, and headache can be increased when Tadalafil is combined with Paliperidone.
Frovatriptan	Frovatriptan The risk or severity of adverse effects can be increased when Frovatriptan is combined with Paliperidone.
Gemifloxacin	Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Paliperidone.
Progesterone	Progesterone The metabolism of Paliperidone can be decreased when combined with Progesterone.
Apomorphine Injection	Apomorphine Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Paliperidone.
Infliximab Injection	Infliximab Injection The metabolism of Paliperidone can be increased when combined with Infliximab.
Protriptyline	Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Paliperidone.
Rifaximin	Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Paliperidone.
Duloxetine	Duloxetine The metabolism of Paliperidone can be decreased when combined with Duloxetine.
Norethindrone	Norethindrone The metabolism of Paliperidone can be decreased when combined with Norethisterone.
Tinidazole	Tinidazole Tinidazole may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Trospium	Trospium Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Bosentan	Bosentan Paliperidone may decrease the antihypertensive activities of Bosentan.
Cefditoren	Cefditoren Cefdinir may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cinacalcet	Cinacalcet The metabolism of Paliperidone can be decreased when combined with Cinacalcet.
Cyanocobalamin Injection	Cyanocobalamin Injection Hydroxocobalamin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Erlotinib	Erlotinib The metabolism of Paliperidone can be decreased when combined with Erlotinib.
Eszopiclone	Eszopiclone The risk or severity of CNS depression can be increased when Paliperidone is combined with Eszopiclone.
Ganciclovir	Ganciclovir Ganciclovir may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Insulin Aspart (rDNA Origin) Injection	Insulin Aspart (rDNA Origin) Injection The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Paliperidone.
Ribavirin	Ribavirin Ribavirin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Solifenacin	Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Paliperidone.
Valganciclovir	Valganciclovir Paliperidone may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Voriconazole	Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Paliperidone.
Adefovir	Adefovir Adefovir may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Dextroamphetamine	Dextroamphetamine The therapeutic efficacy of Paliperidone can be decreased when used in combination with Amphetamine.
Peginterferon Alfa-2b (PEG-Intron)	Peginterferon Alfa-2b (PEG-Intron) The metabolism of Paliperidone can be decreased when combined with Peginterferon alfa-2b.
Pramlintide Injection	Pramlintide Injection The therapeutic efficacy of Pramlintide can be decreased when used in combination with Paliperidone.
Sodium Oxybate	Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Exenatide Injection	Exenatide Injection The therapeutic efficacy of Exenatide can be decreased when used in combination with Paliperidone.
Ibandronate	Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Paliperidone.
Isocarboxazid	Isocarboxazid The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Paliperidone.
Ramelteon	Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Paliperidone.
Darifenacin	Darifenacin The metabolism of Darifenacin can be decreased when combined with Paliperidone.
Fentanyl	Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Paliperidone.
Pregabalin	Pregabalin The therapeutic efficacy of Paliperidone can be increased when used in combination with Pregabalin.
Phenylephrine	Phenylephrine The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Paliperidone.
Tipranavir	Tipranavir The serum concentration of Tipranavir can be decreased when it is combined with Paliperidone.
Felbamate	Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Paliperidone.
Insulin Detemir (rDNA Origin) Injection	Insulin Detemir (rDNA Origin) Injection The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Paliperidone.
Ranolazine	Ranolazine The serum concentration of Paliperidone can be increased when it is combined with Ranolazine.
Abatacept Injection	Abatacept Injection The metabolism of Paliperidone can be increased when combined with Abatacept.
Rasagiline	Rasagiline The risk or severity of adverse effects can be increased when Paliperidone is combined with Rasagiline.
Imatinib	Imatinib The risk or severity of QTc prolongation can be increased when Imatinib is combined with Paliperidone.
Sitagliptin	Sitagliptin The serum concentration of Sitagliptin can be increased when it is combined with Paliperidone.
Varenicline	Varenicline Paliperidone may decrease the excretion rate of Varenicline which could result in a higher serum level.
Gefitinib	Gefitinib The metabolism of Paliperidone can be decreased when combined with Gefitinib.
Albuterol	Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Paliperidone.
Bortezomib	Bortezomib The serum concentration of Paliperidone can be increased when it is combined with Bortezomib.
Clofarabine Injection	Clofarabine Injection Clofarabine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Insulin Glulisine (rDNA origin) Injection	Insulin Glulisine (rDNA origin) Injection The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Paliperidone.
Lubiprostone	Lubiprostone Lubiprostone may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Oxaliplatin Injection	Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Paliperidone.
Posaconazole	Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Paliperidone.
Primaquine	Primaquine The metabolism of Paliperidone can be decreased when combined with Primaquine.
Aliskiren	Aliskiren Paliperidone may decrease the antihypertensive activities of Aliskiren.
Bismuth Subsalicylate	Bismuth Subsalicylate Paliperidone may increase the neurotoxic activities of Bismuth subsalicylate.
Pemetrexed Injection	Pemetrexed Injection Paliperidone may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Dimenhydrinate	Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Paliperidone.
Lisdexamfetamine	Lisdexamfetamine The therapeutic efficacy of Paliperidone can be decreased when used in combination with Lisdexamfetamine.
Nabilone	Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Vorinostat	Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Paliperidone.
Sorafenib	Sorafenib The metabolism of Paliperidone can be decreased when combined with Sorafenib.
Sunitinib	Sunitinib The metabolism of Paliperidone can be decreased when combined with Sunitinib.
Dronabinol	Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Lapatinib	Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Paliperidone.
Levocetirizine	Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Paliperidone.
Pegaptanib Injection	Pegaptanib Injection Paliperidone may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Dasatinib	Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Paliperidone.
Mexiletine	Mexiletine The metabolism of Paliperidone can be decreased when combined with Mexiletine.
Armodafinil	Armodafinil The metabolism of Paliperidone can be increased when combined with Armodafinil.
Azacitidine Injection	Azacitidine Injection Azacitidine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Temsirolimus	Temsirolimus The serum concentration of Temsirolimus can be increased when it is combined with Paliperidone.
Lenalidomide	Lenalidomide Lenalidomide may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Nilotinib	Nilotinib The metabolism of Nilotinib can be decreased when combined with Paliperidone.
Toremifene	Toremifene The risk or severity of QTc prolongation can be increased when Toremifene is combined with Paliperidone.
Budesonide	Budesonide The metabolism of Paliperidone can be increased when combined with Budesonide.
Chloramphenicol Injection	Chloramphenicol Injection The metabolism of Paliperidone can be decreased when combined with Chloramphenicol.
Desmopressin	Desmopressin Desmopressin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
OnabotulinumtoxinA Injection	OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Paliperidone.
RimabotulinumtoxinB Injection	RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Paliperidone.
Doripenem Injection	Doripenem Injection Paliperidone may decrease the excretion rate of Doripenem which could result in a higher serum level.
Etravirine	Etravirine The serum concentration of Paliperidone can be decreased when it is combined with Etravirine.
Arsenic Trioxide Injection	Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Paliperidone.
Desvenlafaxine	Desvenlafaxine The risk or severity of adverse effects can be increased when Paliperidone is combined with Desvenlafaxine.
Cevimeline	Cevimeline Cevimeline may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Nebivolol	Nebivolol Nebivolol may increase the orthostatic hypotensive activities of Paliperidone.
Tretinoin	Tretinoin The metabolism of Paliperidone can be decreased when combined with Tretinoin.
Bendamustine Injection	Bendamustine Injection The serum concentration of Bendamustine can be increased when it is combined with Paliperidone.
Flecainide	Flecainide The metabolism of Flecainide can be decreased when combined with Paliperidone.
Certolizumab Injection	Certolizumab Injection The metabolism of Paliperidone can be increased when combined with Certolizumab pegol.
Irinotecan Injection	Irinotecan Injection The metabolism of Paliperidone can be decreased when combined with Irinotecan.
Daptomycin Injection	Daptomycin Injection Daptomycin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Praziquantel	Praziquantel The metabolism of Paliperidone can be decreased when combined with Praziquantel.
Methylnaltrexone Injection	Methylnaltrexone Injection Paliperidone may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Rufinamide	Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Paliperidone.
Silodosin	Silodosin The serum concentration of Silodosin can be increased when it is combined with Paliperidone.
Midazolam	Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Paliperidone.
Naltrexone Injection	Naltrexone Injection The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Paliperidone.
Dexrazoxane Injection	Dexrazoxane Injection Dexrazoxane may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Milnacipran	Milnacipran The risk or severity of adverse effects can be increased when Paliperidone is combined with Milnacipran.
Plerixafor Injection	Plerixafor Injection Paliperidone may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Fesoterodine	Fesoterodine Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Degarelix Injection	Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Paliperidone.
Betaxolol	Betaxolol The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Paliperidone.
Iloperidone	Iloperidone Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Iloperidone.
Prasugrel	Prasugrel Paliperidone may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Lacosamide	Lacosamide The risk or severity of adverse effects can be increased when Paliperidone is combined with Lacosamide.
Everolimus	Everolimus The serum concentration of Everolimus can be increased when it is combined with Paliperidone.
Tolvaptan (low blood sodium)	Tolvaptan (low blood sodium) The serum concentration of Tolvaptan can be increased when it is combined with Paliperidone.
Dronedarone	Dronedarone Paliperidone may increase the QTc-prolonging activities of Dronedarone.
AbobotulinumtoxinA Injection	AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Paliperidone.
Pralatrexate Injection	Pralatrexate Injection Paliperidone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Palonosetron Injection	Palonosetron Injection The risk or severity of adverse effects can be increased when Palonosetron is combined with Paliperidone.
Saxagliptin	Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Paliperidone.
Telavancin Injection	Telavancin Injection The risk or severity of QTc prolongation can be increased when Telavancin is combined with Paliperidone.
Romidepsin Injection	Romidepsin Injection The serum concentration of Romidepsin can be increased when it is combined with Paliperidone.
Tapentadol	Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Topotecan	Topotecan The serum concentration of Topotecan can be increased when it is combined with Paliperidone.
Golimumab Injection	Golimumab Injection The metabolism of Paliperidone can be increased when combined with Golimumab.
Pazopanib	Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Paliperidone.
Asenapine	Asenapine Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Asenapine.
Vigabatrin	Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Paliperidone.
Levonorgestrel	Levonorgestrel The metabolism of Paliperidone can be decreased when combined with Levonorgestrel.
Oxymorphone	Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Paliperidone.
Liraglutide Injection	Liraglutide Injection The therapeutic efficacy of Liraglutide can be decreased when used in combination with Paliperidone.
Tocilizumab Injection	Tocilizumab Injection The metabolism of Paliperidone can be increased when combined with Tocilizumab.
Dalfampridine	Dalfampridine Paliperidone may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
Eribulin Injection	Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Paliperidone.
IncobotulinumtoxinA Injection	IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Paliperidone.
Cabazitaxel Injection	Cabazitaxel Injection The serum concentration of Cabazitaxel can be increased when it is combined with Paliperidone.
Ceftaroline Injection	Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Lurasidone	Lurasidone Paliperidone may increase the hypotensive activities of Lurasidone.
Acetaminophen Injection	Acetaminophen Injection Acetaminophen may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Vilazodone	Vilazodone The metabolism of Vilazodone can be decreased when combined with Paliperidone.
Ipilimumab Injection	Ipilimumab Injection Paliperidone may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Denileukin Diftitox Injection	Denileukin Diftitox Injection Aldesleukin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Terbutaline Injection	Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Paliperidone.
Roflumilast	Roflumilast Paliperidone may decrease the excretion rate of Roflumilast which could result in a higher serum level.
Linagliptin	Linagliptin The serum concentration of Linagliptin can be increased when it is combined with Paliperidone.
Rilpivirine	Rilpivirine The metabolism of Rilpivirine can be decreased when combined with Paliperidone.
Telaprevir	Telaprevir The serum concentration of Glecaprevir can be increased when it is combined with Paliperidone.
Cyclophosphamide Injection	Cyclophosphamide Injection The metabolism of Paliperidone can be decreased when combined with Cyclophosphamide.
Abiraterone	Abiraterone The metabolism of Paliperidone can be decreased when combined with Abiraterone.
Triptorelin Injection	Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Paliperidone.
Rivaroxaban	Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Paliperidone.
Ticagrelor	Ticagrelor The serum concentration of Ticagrelor can be increased when it is combined with Paliperidone.
Brentuximab Vedotin Injection	Brentuximab Vedotin Injection The serum concentration of Brentuximab vedotin can be increased when it is combined with Paliperidone.
Ruxolitinib	Ruxolitinib Paliperidone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Vandetanib	Vandetanib The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Vandetanib.
Clobazam	Clobazam The metabolism of Paliperidone can be decreased when combined with Clobazam.
Vemurafenib	Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Paliperidone.
Ivacaftor	Ivacaftor The serum concentration of Paliperidone can be increased when it is combined with Ivacaftor.
Deferiprone	Deferiprone Paliperidone may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Axitinib	Axitinib The serum concentration of Axitinib can be increased when it is combined with Paliperidone.
Crizotinib	Crizotinib The serum concentration of Paliperidone can be increased when it is combined with Crizotinib.
Cabergoline	Cabergoline The serum concentration of Paliperidone can be increased when it is combined with Cabergoline.
Naloxone Injection	Naloxone Injection Naloxone may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Ambrisentan	Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Paliperidone.
Fondaparinux Injection	Fondaparinux Injection Fondaparinux may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Ezogabine	Ezogabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Paliperidone.
Carfilzomib Injection	Carfilzomib Injection The serum concentration of Carfilzomib can be increased when it is combined with Paliperidone.
Enzalutamide	Enzalutamide The serum concentration of Paliperidone can be increased when it is combined with Enzalutamide.
Mirabegron	Mirabegron The metabolism of Paliperidone can be decreased when combined with Mirabegron.
Regorafenib	Regorafenib The serum concentration of Regorafenib can be increased when it is combined with Paliperidone.
Bosutinib	Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Paliperidone.
Lorcaserin	Lorcaserin The therapeutic efficacy of Mecasermin can be decreased when used in combination with Paliperidone.
Teduglutide Injection	Teduglutide Injection Paliperidone may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Bedaquiline	Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Paliperidone.
Alogliptin	Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Paliperidone.
Ponatinib	Ponatinib The metabolism of Ponatinib can be decreased when combined with Paliperidone.
Pomalidomide	Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Paliperidone.
Ado-trastuzumab Emtansine Injection	Ado-trastuzumab Emtansine Injection The serum concentration of Trastuzumab emtansine can be increased when it is combined with Paliperidone.
Apixaban	Apixaban The serum concentration of Apixaban can be increased when it is combined with Paliperidone.
Canagliflozin	Canagliflozin The serum concentration of Canagliflozin can be increased when it is combined with Paliperidone.
Methazolamide	Methazolamide Methazolamide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Dabrafenib	Dabrafenib The serum concentration of Paliperidone can be increased when it is combined with Dabrafenib.
Ospemifene	Ospemifene The metabolism of Paliperidone can be decreased when combined with Ospemifene.
Trametinib	Trametinib Paliperidone may decrease the excretion rate of Trametinib which could result in a higher serum level.
Dolutegravir	Dolutegravir The serum concentration of Dolutegravir can be increased when it is combined with Paliperidone.
Afatinib	Afatinib The serum concentration of Afatinib can be increased when it is combined with Paliperidone.
Levomilnacipran	Levomilnacipran The risk or severity of adverse effects can be increased when Paliperidone is combined with Levomilnacipran.
Ertapenem Injection	Ertapenem Injection Ertapenem may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Vortioxetine	Vortioxetine The risk or severity of adverse effects can be increased when Paliperidone is combined with Vortioxetine.
Perampanel	Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Ibrutinib	Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Paliperidone.
Lomitapide	Lomitapide The serum concentration of Lomitapide can be increased when it is combined with Paliperidone.
Avanafil	Avanafil The risk or severity of hypotension, dyspepsia, and headache can be increased when Avanafil is combined with Paliperidone.
Ketorolac Injection	Ketorolac Injection Ketorolac may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Simeprevir	Simeprevir The serum concentration of Simeprevir can be increased when it is combined with Paliperidone.
Sofosbuvir	Sofosbuvir The serum concentration of Sofosbuvir can be increased when it is combined with Paliperidone.
Dapagliflozin	Dapagliflozin The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Paliperidone.
Apremilast	Apremilast The metabolism of Paliperidone can be increased when combined with Apremilast.
Droxidopa	Droxidopa The therapeutic efficacy of Droxidopa can be decreased when used in combination with Paliperidone.
Ceritinib	Ceritinib The serum concentration of Paliperidone can be increased when it is combined with Ceritinib.
Siltuximab Injection	Siltuximab Injection The metabolism of Paliperidone can be increased when combined with Siltuximab.
Albiglutide Injection	Albiglutide Injection The therapeutic efficacy of Albiglutide can be decreased when used in combination with Paliperidone.
Eslicarbazepine	Eslicarbazepine The risk or severity of adverse effects can be increased when Paliperidone is combined with Eslicarbazepine.
Belinostat Injection	Belinostat Injection The serum concentration of Belinostat can be increased when it is combined with Paliperidone.
Idelalisib	Idelalisib The serum concentration of Idelalisib can be increased when it is combined with Paliperidone.
Testosterone Injection	Testosterone Injection Testosterone may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Oritavancin Injection	Oritavancin Injection The metabolism of Paliperidone can be decreased when combined with Oritavancin.
Empagliflozin	Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Paliperidone.
Vorapaxar	Vorapaxar The serum concentration of Paliperidone can be increased when it is combined with Vorapaxar.
Hydrocodone	Hydrocodone Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Suvorexant	Suvorexant Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Dulaglutide Injection	Dulaglutide Injection The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Paliperidone.
Edoxaban	Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Paliperidone.
Olaparib	Olaparib The metabolism of Olaparib can be decreased when combined with Paliperidone.
Methamphetamine	Methamphetamine The therapeutic efficacy of Paliperidone can be decreased when used in combination with Metamfetamine.
Tasimelteon	Tasimelteon The risk or severity of adverse effects can be increased when Paliperidone is combined with Tasimelteon.
Riociguat	Riociguat Paliperidone may decrease the antihypertensive activities of Riociguat.
Nintedanib	Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Paliperidone.
Secukinumab Injection	Secukinumab Injection The metabolism of Paliperidone can be increased when combined with Secukinumab.
Risperidone Injection	Risperidone Injection The risk or severity of adverse effects can be increased when Risperidone is combined with Paliperidone.
Palbociclib	Palbociclib The serum concentration of Palbociclib can be increased when it is combined with Paliperidone.
Insulin Human Inhalation	Insulin Human Inhalation The therapeutic efficacy of Insulin human can be decreased when used in combination with Paliperidone.
Lenvatinib	Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Paliperidone.
Naloxegol	Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Paliperidone.
Panobinostat	Panobinostat The metabolism of Paliperidone can be decreased when combined with Panobinostat.
Haloperidol Injection	Haloperidol Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Paliperidone.
Ivabradine	Ivabradine The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Ivabradine.
Amiloride	Amiloride Amiloride may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Isavuconazonium Injection	Isavuconazonium Injection The serum concentration of Paliperidone can be increased when it is combined with Isavuconazonium.
Macitentan	Macitentan Paliperidone may decrease the excretion rate of Macitentan which could result in a higher serum level.
Flibanserin	Flibanserin The serum concentration of Paliperidone can be increased when it is combined with Flibanserin.
Rolapitant	Rolapitant The metabolism of Paliperidone can be decreased when combined with Rolapitant.
Daclatasvir	Daclatasvir The serum concentration of Paliperidone can be increased when it is combined with Daclatasvir.
Brexpiprazole	Brexpiprazole Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Brexpiprazole.
Ziprasidone Injection	Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Paliperidone.
Cariprazine	Cariprazine The risk or severity of adverse effects can be increased when Paliperidone is combined with Cariprazine.
Penicillin G Procaine Injection	Penicillin G Procaine Injection Paliperidone may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Eluxadoline	Eluxadoline The risk or severity of serotonin syndrome can be increased when Paliperidone is combined with Eluxadoline.
Insulin Degludec (rDNA Origin) Injection	Insulin Degludec (rDNA Origin) Injection The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Paliperidone.
Cobimetinib	Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Paliperidone.
Trabectedin Injection	Trabectedin Injection The metabolism of Trabectedin can be decreased when combined with Paliperidone.
Osimertinib	Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Paliperidone.
Ixazomib	Ixazomib Paliperidone may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Lesinurad	Lesinurad Paliperidone may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Amphotericin B Liposomal Injection	Amphotericin B Liposomal Injection Amphotericin B may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Dexamethasone Injection	Dexamethasone Injection The metabolism of Paliperidone can be increased when combined with Dexamethasone.
Brivaracetam Injection	Brivaracetam Injection The risk or severity of adverse effects can be increased when Paliperidone is combined with Brivaracetam.
Venetoclax	Venetoclax The serum concentration of Venetoclax can be increased when it is combined with Paliperidone.
Cobicistat	Cobicistat The metabolism of Paliperidone can be decreased when combined with Cobicistat.
Midodrine	Midodrine The therapeutic efficacy of Midodrine can be decreased when used in combination with Paliperidone.
Selexipag	Selexipag The serum concentration of Selexipag can be increased when it is combined with Paliperidone.
Pimavanserin	Pimavanserin The risk or severity of adverse effects can be increased when Paliperidone is combined with Pimavanserin.
Diphenhydramine Injection	Diphenhydramine Injection The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Paliperidone.
Furosemide Injection	Furosemide Injection Furosemide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Rucaparib	Rucaparib The metabolism of Rucaparib can be decreased when combined with Paliperidone.
Lixisenatide Injection	Lixisenatide Injection The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Paliperidone.
Ribociclib	Ribociclib The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Ribociclib.
Doxepin (Insomnia)	Doxepin (Insomnia) Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.
Deutetrabenazine	Deutetrabenazine The risk or severity of adverse effects can be increased when Paliperidone is combined with Deutetrabenazine.
Valbenazine	Valbenazine Paliperidone may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Deflazacort	Deflazacort The metabolism of Paliperidone can be increased when combined with Deflazacort.
Safinamide	Safinamide The therapeutic efficacy of Safinamide can be decreased when used in combination with Paliperidone.
Naldemedine	Naldemedine Paliperidone may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Midostaurin	Midostaurin The metabolism of Paliperidone can be decreased when combined with Midostaurin.
Neratinib	Neratinib The serum concentration of Paliperidone can be increased when it is combined with Neratinib.
Enasidenib	Enasidenib The metabolism of Paliperidone can be decreased when combined with Enasidenib.
Inotuzumab Ozogamicin Injection	Inotuzumab Ozogamicin Injection The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Paliperidone.
Benznidazole	Benznidazole Paliperidone may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Copanlisib Injection	Copanlisib Injection The serum concentration of Copanlisib can be increased when it is combined with Paliperidone.
Delafloxacin	Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Paliperidone.
Abemaciclib	Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Paliperidone.
Betrixaban	Betrixaban The serum concentration of Betrixaban can be increased when it is combined with Paliperidone.
Acalabrutinib	Acalabrutinib The metabolism of Paliperidone can be decreased when combined with Acalabrutinib.
Letermovir	Letermovir The metabolism of Paliperidone can be decreased when combined with Letermovir.
Semaglutide Injection	Semaglutide Injection The therapeutic efficacy of Semaglutide can be decreased when used in combination with Paliperidone.
Tetrabenazine	Tetrabenazine The risk or severity of adverse effects can be increased when Paliperidone is combined with Tetrabenazine.
Ertugliflozin	Ertugliflozin The serum concentration of Ertugliflozin can be increased when it is combined with Paliperidone.
Buprenorphine Injection	Buprenorphine Injection Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide	Apalutamide The serum concentration of Paliperidone can be decreased when it is combined with Apalutamide.
Fostamatinib	Fostamatinib The risk or severity of hypotension, dyspepsia, and headache can be increased when Fostamatinib is combined with Paliperidone.
Avatrombopag	Avatrombopag The serum concentration of Avatrombopag can be increased when it is combined with Paliperidone.
Baricitinib	Baricitinib The serum concentration of Baricitinib can be increased when it is combined with Paliperidone.
Lofexidine	Lofexidine The therapeutic efficacy of Paliperidone can be increased when used in combination with Lofexidine.
Plazomicin Injection	Plazomicin Injection Paliperidone may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Eliglustat	Eliglustat The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Eliglustat.
Encorafenib	Encorafenib The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Encorafenib.
Binimetinib	Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Paliperidone.
Ivosidenib	Ivosidenib The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Paliperidone.
Lusutrombopag	Lusutrombopag The serum concentration of Lusutrombopag can be increased when it is combined with Paliperidone.
Elagolix	Elagolix The serum concentration of Elagolix can be increased when it is combined with Paliperidone.
Doravirine	Doravirine The metabolism of Doravirine can be decreased when combined with Paliperidone.
Tafenoquine	Tafenoquine The metabolism of Tafenoquine can be decreased when combined with Paliperidone.
Cannabidiol	Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Paliperidone.
Dacomitinib	Dacomitinib The serum concentration of Paliperidone can be increased when it is combined with Dacomitinib.
Duvelisib	Duvelisib The serum concentration of Duvelisib can be increased when it is combined with Paliperidone.
Omadacycline	Omadacycline The serum concentration of Omadacycline can be increased when it is combined with Paliperidone.
Sarecycline	Sarecycline The serum concentration of Paliperidone can be increased when it is combined with Sarecycline.
Stiripentol	Stiripentol The metabolism of Paliperidone can be decreased when combined with Stiripentol.
Talazoparib	Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Paliperidone.
Gilteritinib	Gilteritinib The therapeutic efficacy of Paliperidone can be decreased when used in combination with Gilteritinib.
Glasdegib	Glasdegib The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Glasdegib.
Lorlatinib	Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Paliperidone.
Larotrectinib	Larotrectinib The serum concentration of Larotrectinib can be increased when it is combined with Paliperidone.
Paclitaxel (with albumin) Injection	Paclitaxel (with albumin) Injection The metabolism of Paclitaxel can be decreased when combined with Paliperidone.
Rifamycin	Rifamycin The serum concentration of Rifamycin can be increased when it is combined with Paliperidone.
Prucalopride	Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Paliperidone.
Emapalumab-lzsg Injection	Emapalumab-lzsg Injection The metabolism of Paliperidone can be increased when combined with Emapalumab.
Siponimod	Siponimod The risk or severity of hypertension can be increased when Paliperidone is combined with Siponimod.
Acyclovir Ophthalmic	Acyclovir Ophthalmic Acyclovir may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Erdafitinib	Erdafitinib The serum concentration of Paliperidone can be increased when it is combined with Erdafitinib.
Brexanolone Injection	Brexanolone Injection The risk or severity of adverse effects can be increased when Paliperidone is combined with Brexanolone.
Solriamfetol	Solriamfetol The risk or severity of hypertension can be increased when Solriamfetol is combined with Paliperidone.
Darolutamide	Darolutamide The serum concentration of Darolutamide can be increased when it is combined with Paliperidone.
Triclabendazole	Triclabendazole The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Paliperidone.
Entrectinib	Entrectinib The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Entrectinib.
Istradefylline	Istradefylline The serum concentration of Istradefylline can be increased when it is combined with Paliperidone.
Pitolisant	Pitolisant The serum concentration of Paliperidone can be decreased when it is combined with Pitolisant.
Fedratinib	Fedratinib The serum concentration of Fedratinib can be increased when it is combined with Paliperidone.
Lefamulin	Lefamulin Paliperidone may increase the QTc-prolonging activities of Lefamulin.
Phenytoin Injection	Phenytoin Injection The risk or severity of adverse effects can be increased when Phenytoin is combined with Paliperidone.
Fosphenytoin Injection	Fosphenytoin Injection The risk or severity of adverse effects can be increased when Paliperidone is combined with Fosphenytoin.
Enfortumab vedotin-ejfv Injection	Enfortumab vedotin-ejfv Injection The serum concentration of Enfortumab vedotin can be increased when it is combined with Paliperidone.
Lumateperone	Lumateperone The risk or severity of adverse effects can be increased when Paliperidone is combined with Lumateperone.
Lasmiditan	Lasmiditan The risk or severity of serotonin syndrome can be increased when Paliperidone is combined with Lasmiditan.
Ubrogepant	Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Paliperidone.
Tazemetostat	Tazemetostat The serum concentration of Tazemetostat can be increased when it is combined with Paliperidone.
Cenobamate	Cenobamate The serum concentration of Paliperidone can be decreased when it is combined with Cenobamate.
Selumetinib	Selumetinib The serum concentration of Selumetinib can be increased when it is combined with Paliperidone.
Rimegepant	Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Paliperidone.
Tucatinib	Tucatinib Paliperidone may decrease the excretion rate of Tucatinib which could result in a higher serum level.
Remdesivir Injection	Remdesivir Injection The serum concentration of Remdesivir can be increased when it is combined with Paliperidone.
Ripretinib	Ripretinib The serum concentration of Ripretinib can be increased when it is combined with Paliperidone.
Selpercatinib	Selpercatinib The risk or severity of hypertension can be increased when Paliperidone is combined with Selpercatinib.
Lemborexant	Lemborexant The risk or severity of adverse effects can be increased when Paliperidone is combined with Lemborexant.
Fenfluramine	Fenfluramine The risk or severity of serotonin syndrome can be increased when Fenfluramine is combined with Paliperidone.
Fostemsavir	Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Paliperidone.
Octreotide	Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Paliperidone.
Belantamab Mafodotin-blmf Injection	Belantamab Mafodotin-blmf Injection The serum concentration of Belantamab mafodotin can be increased when it is combined with Paliperidone.
Pralsetinib	Pralsetinib The serum concentration of Pralsetinib can be increased when it is combined with Paliperidone.
Opicapone	Opicapone The therapeutic efficacy of Opicapone can be decreased when used in combination with Paliperidone.
Satralizumab-mwge Injection	Satralizumab-mwge Injection The serum concentration of Paliperidone can be decreased when it is combined with Satralizumab.
Naxitamab-gqgk Injection	Naxitamab-gqgk Injection The risk or severity of hypertension can be increased when Paliperidone is combined with Naxitamab.
Relugolix	Relugolix The serum concentration of Relugolix can be increased when it is combined with Paliperidone.
Progestin-Only (drospirenone) Oral Contraceptives	Progestin-Only (drospirenone) Oral Contraceptives Drospirenone may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Viloxazine	Viloxazine The risk or severity of adverse effects can be increased when Paliperidone is combined with Viloxazine.
Tobramycin Injection	Tobramycin Injection Tobramycin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Theophylline	Theophylline The metabolism of Paliperidone can be decreased when combined with Theophylline.
Fenoprofen	Fenoprofen Fenoprofen may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Indomethacin	Indomethacin Indomethacin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Mefenamic Acid	Mefenamic Acid Mefenamic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Naproxen	Naproxen Naproxen may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Tolmetin	Tolmetin Tolmetin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Sulindac	Sulindac Sulindac may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Trazodone	Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Paliperidone.
Isotretinoin	Isotretinoin Isotretinoin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Sucralfate	Sucralfate Sucralfate may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Hydroxyurea	Hydroxyurea The metabolism of Paliperidone can be decreased when combined with Hydroxyurea.
Floxuridine	Floxuridine Floxuridine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Phenobarbital	Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Paliperidone.
Metaxalone	Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Paliperidone.
Methotrexate Injection	Methotrexate Injection Methotrexate may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Levorphanol	Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Paliperidone.
Primidone	Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Paliperidone.
Methsuximide	Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Paliperidone.
Diethylpropion	Diethylpropion The therapeutic efficacy of Paliperidone can be decreased when used in combination with Diethylpropion.
Chlorpromazine	Chlorpromazine Chlorpromazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Diazepam	Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Paliperidone.
Oxazepam	Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Paliperidone.
Flurazepam	Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Paliperidone.
Clorazepate	Clorazepate The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Paliperidone.
Lorazepam	Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Paliperidone.
Phenoxybenzamine	Phenoxybenzamine Phenoxybenzamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Carmustine	Carmustine Carmustine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Amantadine	Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Paliperidone.
Codeine	Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Paliperidone.
Meprobamate	Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Paliperidone.
Chlordiazepoxide	Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Paliperidone.
Bromocriptine	Bromocriptine Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Metaproterenol	Metaproterenol The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Paliperidone.
Tranylcypromine	Tranylcypromine The metabolism of Paliperidone can be decreased when combined with Tranylcypromine.
Phenelzine	Phenelzine The risk or severity of adverse effects can be increased when Phenelzine is combined with Paliperidone.
Procarbazine	Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Paliperidone.
Ergoloid Mesylates	Ergoloid Mesylates The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Paliperidone.
Tetracycline	Tetracycline Tetracycline may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Minocycline	Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Prochlorperazine	Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Paliperidone.
Thioridazine	Thioridazine Thioridazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Trifluoperazine	Trifluoperazine Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Bleomycin	Bleomycin Bleomycin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Dapsone	Dapsone The metabolism of Paliperidone can be decreased when combined with Dapsone.
Sulfadiazine	Sulfadiazine The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Paliperidone.
Oxycodone	Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Paliperidone.
Methadone	Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Paliperidone.
Oxybutynin	Oxybutynin The metabolism of Paliperidone can be decreased when combined with Oxybutynin.
Benztropine	Benztropine The risk or severity of adverse effects can be increased when Paliperidone is combined with Benzatropine.
Maprotiline	Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Paliperidone.
Ibuprofen	Ibuprofen Ibuprofen may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Trihexyphenidyl	Trihexyphenidyl The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Paliperidone.
Orphenadrine	Orphenadrine Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine	Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Paliperidone.
Azathioprine	Azathioprine Azathioprine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Fluphenazine	Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Paliperidone.
Phentermine	Phentermine The therapeutic efficacy of Paliperidone can be decreased when used in combination with Phentermine.
Methylphenidate	Methylphenidate The risk or severity of adverse effects can be increased when Paliperidone is combined with Methylphenidate.
Amoxapine	Amoxapine Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amoxapine.
Sulfasalazine	Sulfasalazine Sulfasalazine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Hydrocortisone	Hydrocortisone The metabolism of Paliperidone can be decreased when combined with Hydrocortisone.
Doxorubicin	Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Paliperidone.
Dactinomycin	Dactinomycin The serum concentration of Paliperidone can be increased when it is combined with Dactinomycin.
Phenazopyridine	Phenazopyridine Phenazopyridine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Carbamazepine	Carbamazepine The metabolism of Paliperidone can be decreased when combined with Carbamazepine.
Molindone	Molindone The risk or severity of adverse effects can be increased when Paliperidone is combined with Molindone.
Methyldopa	Methyldopa The therapeutic efficacy of Paliperidone can be decreased when used in combination with Methyldopa.
Clonidine	Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Paliperidone.
Prazosin	Prazosin Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Hydralazine	Hydralazine Paliperidone may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Cimetidine	Cimetidine The metabolism of Paliperidone can be decreased when combined with Cimetidine.
Gentamicin Injection	Gentamicin Injection Gentamicin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Warfarin	Warfarin Paliperidone may decrease the excretion rate of Warfarin which could result in a higher serum level.
Clonazepam	Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Paliperidone.
Loperamide	Loperamide The risk or severity of QTc prolongation can be increased when Loperamide is combined with Paliperidone.
Promethazine	Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Paliperidone.
Meclofenamate	Meclofenamate Meclofenamic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Daunorubicin	Daunorubicin The metabolism of Paliperidone can be increased when combined with Daunorubicin.
Nitrofurantoin	Nitrofurantoin Nitrofurantoin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Digoxin	Digoxin Paliperidone may decrease the excretion rate of Digoxin which could result in a higher serum level.
Loxapine	Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Paliperidone.
Chloroquine	Chloroquine The metabolism of Paliperidone can be decreased when combined with Chloroquine.
Quinine	Quinine The metabolism of Paliperidone can be decreased when combined with Quinine.
Ethosuximide	Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Paliperidone.
Triamterene	Triamterene Triamterene may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Chlorothiazide	Chlorothiazide Chlorothiazide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Chlorthalidone	Chlorthalidone Chlorthalidone may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Metolazone	Metolazone Metolazone may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide	Isosorbide Isosorbide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Clindamycin Injection	Clindamycin Injection The metabolism of Paliperidone can be decreased when combined with Clindamycin.
Secobarbital	Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Paliperidone.
Desipramine	Desipramine The metabolism of Paliperidone can be decreased when combined with Desipramine.
Amitriptyline	Amitriptyline Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amitriptyline.
Imipramine	Imipramine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Probenecid	Probenecid Probenecid may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Quinidine	Quinidine Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Quinidine.
Procainamide	Procainamide The metabolism of Procainamide can be decreased when combined with Paliperidone.
Isoniazid	Isoniazid The risk or severity of serotonin syndrome can be increased when Isoniazid is combined with Paliperidone.
Pyrazinamide	Pyrazinamide Pyrazinamide may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Rifampin	Rifampin The serum concentration of Paliperidone can be decreased when it is combined with Rifampicin.
Disopyramide	Disopyramide The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Paliperidone.
Valproic Acid	Valproic Acid The serum concentration of Paliperidone can be increased when it is combined with Valproic acid.
Tamoxifen	Tamoxifen The metabolism of Paliperidone can be decreased when combined with Tamoxifen.
Butabarbital	Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Paliperidone.
Levothyroxine	Levothyroxine The serum concentration of Paliperidone can be decreased when it is combined with Levothyroxine.
Liothyronine	Liothyronine Liothyronine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Methimazole	Methimazole The metabolism of Paliperidone can be decreased when combined with Methimazole.
Chlorpropamide	Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Paliperidone.
Tolbutamide	Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Paliperidone.
Tolazamide	Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Paliperidone.
Dextromethorphan	Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Paliperidone.
Cyclobenzaprine	Cyclobenzaprine The risk or severity of CNS depression can be increased when Paliperidone is combined with Cyclobenzaprine.
Niacin	Niacin The metabolism of Paliperidone can be decreased when combined with Niacin.
Baclofen	Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Paliperidone.
Doxylamine	Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Cyproheptadine	Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Paliperidone.
Clemastine	Clemastine The risk or severity of QTc prolongation can be increased when Clemastine is combined with Paliperidone.
Chlorpheniramine	Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Paliperidone.
Brompheniramine	Brompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Paliperidone.
Meclizine	Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Paliperidone.
Ethambutol	Ethambutol Ethambutol may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Methyclothiazide	Methyclothiazide Methyclothiazide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Hydrochlorothiazide	Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Paliperidone.
Dantrolene	Dantrolene The risk or severity of adverse effects can be increased when Dantrolene is combined with Paliperidone.
Chlorzoxazone	Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Paliperidone.
Carisoprodol	Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Paliperidone.
Methocarbamol	Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Paliperidone.
Pyridoxine	Pyridoxine Pyridoxine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Folic Acid	Folic Acid Folic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Disulfiram	Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Paliperidone.
Propranolol (Cardiovascular)	Propranolol (Cardiovascular) The risk or severity of QTc prolongation can be increased when Propranolol is combined with Paliperidone.
Minoxidil	Minoxidil Paliperidone may decrease the antihypertensive activities of Minoxidil.
Pseudoephedrine	Pseudoephedrine The therapeutic efficacy of Paliperidone can be decreased when used in combination with Pseudoephedrine.
Nortriptyline	Nortriptyline Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nortriptyline.
Spironolactone	Spironolactone Spironolactone may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Amphotericin B Injection	Amphotericin B Injection Amphotericin B may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Phytonadione	Phytonadione Phylloquinone may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Amikacin Injection	Amikacin Injection Amikacin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Nadolol	Nadolol Nadolol may increase the orthostatic hypotensive activities of Paliperidone.
Butorphanol Injection	Butorphanol Injection The risk or severity of adverse effects can be increased when Butorphanol is combined with Paliperidone.
Nalbuphine Injection	Nalbuphine Injection The risk or severity of adverse effects can be increased when Nalbuphine is combined with Paliperidone.
Allopurinol	Allopurinol Allopurinol may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Oxytocin Injection	Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Paliperidone.
Trimethobenzamide	Trimethobenzamide The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Paliperidone.
Clomiphene	Clomiphene The serum concentration of Clomifene can be increased when it is combined with Paliperidone.
Flavoxate	Flavoxate Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine	Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Paliperidone.
Fluorouracil Injection	Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Paliperidone.
Colchicine	Colchicine The serum concentration of Colchicine can be increased when it is combined with Paliperidone.
Cefaclor	Cefaclor Cefaclor may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cefadroxil	Cefadroxil Cefadroxil may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cefazolin Injection	Cefazolin Injection Cefazolin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cephalexin	Cephalexin Cephalexin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cefoxitin Injection	Cefoxitin Injection Cefoxitin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Dacarbazine	Dacarbazine Dacarbazine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Acetazolamide	Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Paliperidone.
Cefotaxime Injection	Cefotaxime Injection Cefotaxime may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Calcitonin Salmon Injection	Calcitonin Salmon Injection Salmon calcitonin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Ketoconazole	Ketoconazole The metabolism of Paliperidone can be decreased when combined with Ketoconazole.
Pyrantel	Pyrantel The risk or severity of adverse effects can be increased when Paliperidone is combined with Pyrantel.
Vincristine Injection	Vincristine Injection The excretion of Vincristine can be decreased when combined with Paliperidone.
Captopril	Captopril Paliperidone may decrease the antihypertensive activities of Captopril.
Dipyridamole	Dipyridamole The risk or severity of hypotension, dyspepsia, and headache can be increased when Dipyridamole is combined with Paliperidone.
Isoxsuprine	Isoxsuprine The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Paliperidone.
Vinblastine	Vinblastine The serum concentration of Vinblastine can be increased when it is combined with Paliperidone.
Ethacrynic Acid	Ethacrynic Acid Etacrynic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Colistimethate Injection	Colistimethate Injection Colistimethate may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Metoprolol	Metoprolol The metabolism of Metoprolol can be decreased when combined with Paliperidone.
Hydroxyzine	Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Paliperidone.
Thiothixene	Thiothixene The risk or severity of adverse effects can be increased when Paliperidone is combined with Thiothixene.
Aspirin	Aspirin Acetylsalicylic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Salsalate	Salsalate Salsalate may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Alprazolam	Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Paliperidone.
Temazepam	Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Paliperidone.
Triazolam	Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Paliperidone.
Dicyclomine	Dicyclomine Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine	Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Paliperidone.
Propantheline	Propantheline Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Trimethoprim	Trimethoprim Trimethoprim may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Diltiazem	Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Paliperidone.
Nifedipine	Nifedipine The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Paliperidone.
Timolol	Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Paliperidone.
Verapamil	Verapamil Verapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Atenolol	Atenolol Atenolol may increase the orthostatic hypotensive activities of Paliperidone.
Pindolol	Pindolol Pindolol may increase the orthostatic hypotensive activities of Paliperidone.
Cisplatin Injection	Cisplatin Injection Paliperidone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Diflunisal	Diflunisal Diflunisal may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Piroxicam	Piroxicam Piroxicam may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Bumetanide	Bumetanide Bumetanide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Etoposide	Etoposide The serum concentration of Paliperidone can be increased when it is combined with Etoposide.
Glyburide	Glyburide The therapeutic efficacy of Paliperidone can be decreased when used in combination with Glyburide.
Glipizide	Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Paliperidone.
Indapamide	Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Paliperidone.
Amoxicillin	Amoxicillin Amoxicillin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Oxacillin Injection	Oxacillin Injection Oxacillin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Pentoxifylline	Pentoxifylline The risk or severity of hypotension, dyspepsia, and headache can be increased when Pentoxifylline is combined with Paliperidone.
Pentamidine Injection	Pentamidine Injection The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Paliperidone.
Ceftriaxone Injection	Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Labetalol	Labetalol Labetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Auranofin	Auranofin Auranofin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Leuprolide Injection	Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Paliperidone.
Gemfibrozil	Gemfibrozil Gemfibrozil may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Guanabenz	Guanabenz The therapeutic efficacy of Guanabenz can be decreased when used in combination with Paliperidone.
Dipivefrin Ophthalmic	Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Ceftazidime Injection	Ceftazidime Injection Ceftazidime may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Ketoprofen	Ketoprofen Ketoprofen may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cefotetan Injection	Cefotetan Injection Cefotetan may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Pimozide	Pimozide The metabolism of Paliperidone can be decreased when combined with Pimozide.
Enalapril	Enalapril Paliperidone may decrease the antihypertensive activities of Enalapril.
Flurbiprofen	Flurbiprofen Flurbiprofen may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Amiodarone	Amiodarone The risk or severity of QTc prolongation can be increased when Amiodarone is combined with Paliperidone.
Aztreonam Injection	Aztreonam Injection Aztreonam may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Buspirone	Buspirone The risk or severity of serotonin syndrome can be increased when Buspirone is combined with Paliperidone.
Lovastatin	Lovastatin The metabolism of Paliperidone can be decreased when combined with Lovastatin.
Ciprofloxacin	Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Paliperidone.
Mesalamine	Mesalamine Mesalazine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Diclofenac	Diclofenac Diclofenac may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Fluoxetine	Fluoxetine The serum concentration of Paliperidone can be increased when it is combined with Fluoxetine.
Nimodipine	Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Paliperidone.
Clozapine	Clozapine Clozapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Estazolam	Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Paliperidone.
Idarubicin	Idarubicin The metabolism of Paliperidone can be decreased when combined with Idarubicin.
Ofloxacin	Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Paliperidone.
Didanosine	Didanosine Didanosine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Pentostatin Injection	Pentostatin Injection Pentostatin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Clarithromycin	Clarithromycin The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Paliperidone.
Benazepril	Benazepril Paliperidone may decrease the antihypertensive activities of Benazepril.
Etodolac	Etodolac Etodolac may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Felodipine	Felodipine The metabolism of Felodipine can be decreased when combined with Paliperidone.
Fosinopril	Fosinopril Fosinopril may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Nabumetone	Nabumetone Nabumetone may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Pravastatin	Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Paliperidone.
Quinapril	Quinapril Paliperidone may decrease the antihypertensive activities of Quinapril.
Ramipril	Ramipril Paliperidone may decrease the antihypertensive activities of Ramipril.
Simvastatin	Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Paliperidone.
Amlodipine	Amlodipine The risk or severity of hypotension can be increased when Paliperidone is combined with Amlodipine.
Teniposide Injection	Teniposide Injection The metabolism of Paliperidone can be decreased when combined with Teniposide.
Itraconazole	Itraconazole The metabolism of Paliperidone can be decreased when combined with Itraconazole.
Lisinopril	Lisinopril Lisinopril may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Oxaprozin	Oxaprozin Oxaprozin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Sotalol	Sotalol The metabolism of Sotalol can be decreased when combined with Paliperidone.
Bisoprolol	Bisoprolol The serum concentration of Paliperidone can be increased when it is combined with Bisoprolol.
Zolpidem	Zolpidem Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin	Doxazosin Doxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Terazosin	Terazosin Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Isradipine	Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Paliperidone.
Omeprazole	Omeprazole The metabolism of Paliperidone can be decreased when combined with Omeprazole.
Cisapride	Cisapride The risk or severity of QTc prolongation can be increased when Cisapride is combined with Paliperidone.
Gabapentin	Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Paliperidone.
Fluvastatin	Fluvastatin The metabolism of Paliperidone can be decreased when combined with Fluvastatin.
Venlafaxine	Venlafaxine The metabolism of Paliperidone can be decreased when combined with Venlafaxine.
Stavudine	Stavudine Stavudine may increase the neurotoxic activities of Paliperidone.
Fluvoxamine	Fluvoxamine The metabolism of Paliperidone can be decreased when combined with Fluvoxamine.
Nefazodone	Nefazodone Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nefazodone.
Lamotrigine	Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Paliperidone.
Losartan	Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Paliperidone.
Valacyclovir	Valacyclovir Valaciclovir may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Tramadol	Tramadol The risk or severity of serotonin syndrome can be increased when Paliperidone is combined with Tramadol.
Vinorelbine Injection	Vinorelbine Injection The metabolism of Paliperidone can be decreased when combined with Vinorelbine.
Carboplatin Injection	Carboplatin Injection Carboplatin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Moexipril	Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Paliperidone.
Lansoprazole	Lansoprazole The metabolism of Paliperidone can be decreased when combined with Lansoprazole.
Ifosfamide Injection	Ifosfamide Injection The metabolism of Paliperidone can be decreased when combined with Ifosfamide.
Nicardipine	Nicardipine Nicardipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Bupropion	Bupropion The metabolism of Paliperidone can be decreased when combined with Bupropion.
Ticlopidine	Ticlopidine The metabolism of Paliperidone can be decreased when combined with Ticlopidine.
Saquinavir	Saquinavir The metabolism of Paliperidone can be decreased when combined with Saquinavir.
Metformin	Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Paliperidone.
Nisoldipine	Nisoldipine The risk or severity of hypotension can be increased when Nisoldipine is combined with Paliperidone.
Lamivudine	Lamivudine Lamivudine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Riluzole	Riluzole The risk or severity of adverse effects can be increased when Riluzole is combined with Paliperidone.
Acarbose	Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Paliperidone.
Glimepiride	Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Paliperidone.
Gemcitabine Injection	Gemcitabine Injection The serum concentration of Paliperidone can be increased when it is combined with Gemcitabine.
Indinavir	Indinavir The metabolism of Paliperidone can be decreased when combined with Indinavir.
Ritonavir	Ritonavir The serum concentration of Paliperidone can be increased when it is combined with Ritonavir.
Docetaxel Injection	Docetaxel Injection The metabolism of Paliperidone can be decreased when combined with Docetaxel.
Cidofovir Injection	Cidofovir Injection Cidofovir may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Meropenem Injection	Meropenem Injection Meropenem may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Clomipramine	Clomipramine The metabolism of Paliperidone can be decreased when combined with Clomipramine.
Fosfomycin	Fosfomycin Fosfomycin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Mirtazapine	Mirtazapine Paliperidone may increase the serotonergic activities of Mirtazapine.
Trandolapril	Trandolapril Paliperidone may decrease the antihypertensive activities of Trandolapril.
Topiramate	Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Paliperidone.
Valsartan	Valsartan Paliperidone may decrease the antihypertensive activities of Valsartan.
Insulin Lispro Injection	Insulin Lispro Injection The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Paliperidone.
Pramipexole	Pramipexole The therapeutic efficacy of Pramipexole can be decreased when used in combination with Paliperidone.
Donepezil	Donepezil The risk or severity of adverse effects can be increased when Donepezil is combined with Paliperidone.
Nelfinavir	Nelfinavir The metabolism of Paliperidone can be decreased when combined with Nelfinavir.
Fexofenadine	Fexofenadine The serum concentration of Paliperidone can be increased when it is combined with Fexofenadine.
Azithromycin	Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Paliperidone.
Carvedilol	Carvedilol Carvedilol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Nilutamide	Nilutamide Nilutamide may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Flutamide	Flutamide Flutamide may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Selegiline	Selegiline The risk or severity of adverse effects can be increased when Selegiline is combined with Paliperidone.
Bicalutamide	Bicalutamide The metabolism of Paliperidone can be decreased when combined with Bicalutamide.
Sertraline	Sertraline The risk or severity of adverse effects can be increased when Sertraline is combined with Paliperidone.
Propafenone	Propafenone The metabolism of Paliperidone can be decreased when combined with Propafenone.
Irbesartan	Irbesartan Paliperidone may decrease the antihypertensive activities of Irbesartan.
Tamsulosin	Tamsulosin Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Ropinirole	Ropinirole The therapeutic efficacy of Ropinirole can be decreased when used in combination with Paliperidone.
Finasteride	Finasteride The metabolism of Paliperidone can be decreased when combined with Finasteride.
Quetiapine	Quetiapine Quetiapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Cefepime Injection	Cefepime Injection Cefepime may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cefprozil	Cefprozil Cefprozil may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cefpodoxime	Cefpodoxime Cefpodoxime may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cetirizine	Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Paliperidone.
Paroxetine	Paroxetine The metabolism of Paliperidone can be decreased when combined with Paroxetine.
Tolcapone	Tolcapone The therapeutic efficacy of Tolcapone can be decreased when used in combination with Paliperidone.
Citalopram	Citalopram The risk or severity of QTc prolongation can be increased when Citalopram is combined with Paliperidone.
Capecitabine	Capecitabine Capecitabine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Efavirenz	Efavirenz The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Paliperidone.
Abacavir	Abacavir Abacavir may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Sildenafil	Sildenafil The serum concentration of Sildenafil can be increased when it is combined with Paliperidone.
Pioglitazone	Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Paliperidone.
Celecoxib	Celecoxib The metabolism of Paliperidone can be decreased when combined with Celecoxib.
Rosiglitazone	Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Paliperidone.
Tolterodine	Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Paliperidone.
Thalidomide	Thalidomide Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Oseltamivir	Oseltamivir Oseltamivir may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Balsalazide	Balsalazide Balsalazide may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Nateglinide	Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Paliperidone.
Galantamine	Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Paliperidone.
Levetiracetam	Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Paliperidone.
Rabeprazole	Rabeprazole Rabeprazole may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Terbinafine	Terbinafine The metabolism of Paliperidone can be decreased when combined with Terbinafine.